Status:
COMPLETED
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Eligibility:
MALE
2+ years
Phase:
PHASE2
Brief Summary
This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment ...
Eligibility Criteria
Inclusion
- Diagnosis of congenital haemophilia A or B with inhibitors development against FVIII or FIX, respectively
Exclusion
- Prophylactic administration of any haemostatic drug within 3 last months prior to entering the trial.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00108758
Start Date
March 1 2004
End Date
November 1 2005
Last Update
January 12 2017
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Berkeley, California, United States, 94704
2
Novo Nordisk Investigational Site
Los Angeles, California, United States, 90027
3
Novo Nordisk Investigational Site
Chicago, Illinois, United States, 60612
4
Novo Nordisk Investigational Site
Indianapolis, Indiana, United States, 46260